Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Feb 2024| PHM113C| BCC Publishing

Report Highlights

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

Report Includes

  • 31 data tables and 63 additional tables
  • An overview of the global market for the technologies for prevention and treatment of prostate cancer
  • Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
  • Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
  • Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
  • Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
  • Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
  • Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
  • Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
  • Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
  • Profiles of leading market participants

Report Scope

This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.

Frequently Asked Questions (FAQs)

The global prostate cancer care market is estimated to be around $37.9 billion in 2023. The market is projected to reach $56.4 billion in 2028, growing at a CAGR of 8.3% during the forecast period.
An in-depth analysis of the global prostate cancer care market, including historical data and market projection on sales by product type and subtypes, and region.
By product type, the pharmaceutical segment is anticipated to dominate the market by the end of 2028.
Pharmaceuticals is the fastest growing market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $35.3 billion
Market size forecast $56.4 billion
Growth rate CAGR of 8.3% from 2023 to 2028
Units considered $ Millions
Segments covered By Type, Subtype, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market Drivers
  • Increasing Prevalence of Prostate Cancer
  • Growing Trend Towards Active Surveillance and Screening
  • Trend Towards Personalized Care
  • Approvals for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Collaborations and Licensing Agreements
Companies studied
  • ABBOTT
  • ACCURAY INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BAYER AG
  • DANAHER CORP.
  • DENDREON PHARMACEUTICALS LLC
  • ELEKTA
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • PFIZER INC.
  • SANOFI
  • SIEMENS HEALTHINEERS AG

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Prevention and Treatment of Prostate Cancer: Technologies and Global Markets157Free
Chapter- 1: Introduction3Free
Chapter- 2: Summary and Highlights4Free
Chapter- 3: Market Overview8Free
Chapter- 4: Market Dynamics12Free
Chapter- 5: Screening and Diagnosis Market by Test Type21Free
Chapter- 6: Pharmaceuticals Market by Drug Type19Free
Chapter- 7: Market for Surgery and Radiation Therapy by Treatment Type13Free
Chapter- 8: Market Breakdown by Region13Free
Chapter- 9: Emerging Technologies and Developments5Free
Chapter- 10: Pipeline Analysis5Free
Chapter- 11: Competitive Intelligence3Free
Chapter- 12: Company Profiles49Free
Chapter- 13: Appendix: Abbreviations2Free
Published - Mar-2017| Analyst - Usha Nagavarapu| Code - PHM113B

Report Highlights

The global market for prostate cancer products reached nearly $47.2 billion in 2016 and should reach nearly $65.1 billion in 2021, with a compound annual growth rate (CAGR) of 6.6%.

Report Includes

  • An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
  • Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
  • Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
  • Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
  • Evaluation of prostate cancer treatment products by geography, race, and category
  • Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
  • Comprehensive company profiles of major players in the field.
Published - Jan-2013| Analyst - Usha Nagavarapu| Code - PHM113A

Report Highlights

The global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.

This report provide:

  • An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
  • Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
  • Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
  • Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
  • Evaluation of prostate cancer treatment products by geography, race, and category
  • Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
  • Comprehensive company profiles.

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS